蛋白质疗法研究商Jocasta Neuroscience获得3500万美元A轮融资，以推进管理认知障碍的长寿蛋白项目-动脉网

Jocasta Neuroscience Lands $35 Million Series A to Advance Longevity Protein Program for Managing Cognitive Impairment

CISION 等信源发布 2025-08-12 22:00



可切换为仅中文







Funding to support development of proprietary * a -Klotho *protein therapeutic targeting cognitive decline in neurodegenerative diseases

为支持开发针对神经退行性疾病中认知衰退的专有*a-Klotho*蛋白治疗药物提供资金

SCOTTSDALE, Ariz.

斯科茨代尔，亚利桑那州

，

Aug. 12, 2025

2025年8月12日

/PRNewswire/ --

Jocasta Neuroscience, Inc.

约卡斯塔神经科学公司

, a preclinical stage, longevity-focused company, with its lead asset, a proprietary formulation of the longevity protein, a - Klotho, for the treatment of conditions, including cognitive impairment in neurodegenerative diseases, today announced it has raised

，一家处于临床前阶段、专注于长寿的公司，其主要资产是一种专有的长寿蛋白制剂——a-Klotho，用于治疗包括神经退行性疾病中的认知障碍在内的疾病，今天宣布已完成融资筹集。

$35 million

3500万美元

in a Series A financing.

在A轮融资中。

The funds will be used to support development of Jocasta's lead a - Klotho compound, JN-0413, through Phase 1 development (including both the Single Ascending Dose and Multiple Ascending Dose studies), with an IND submission slated for Q4 2026.

这笔资金将用于支持 Jocasta 公司的主要 a-Klotho 化合物 JN-0413 的开发，直至第一阶段开发完成（包括单剂量递增和多剂量递增研究），其 IND 申请计划于 2026 年第四季度提交。

The round was led by early-stage venture capital firm True Ventures and joined by Moore Strategic Ventures, SC8 Investments, Glentura, Yagan Family Foundation, and others.

本轮融资由早期风险投资公司 True Ventures 领投，Moore Strategic Ventures、SC8 Investments、Glentura、Yagan Family Foundation 等跟投。

Kevin Rose

凯文·罗斯

of True Ventures will join Dr.

True Ventures 的将加入博士。

Michael Davidson

迈克尔·戴维森

, COB, and Dr.

，COB，和博士。

Albert Agro

阿尔伯特·阿格罗

(CEO) on the Jocasta Board of Directors.

（首席执行官）在乔卡斯塔董事会。

The original technology was developed at the

原始技术是在

University of California at San Francisco

加利福尼亚大学旧金山分校

(UCSF) by Dr.

（UCSF）由博士

Dena Dubal

德纳·杜巴尔

, MD, PhD, a professor of neurology, and the David A. Coulter Endowed Chair in Aging and Neurodegenerative Disease as well, a Cofounder of Jocasta Neurosciences Inc. It was then licensed to Unity Biotechnology, Inc., a publicly traded company based in

医学博士、哲学博士，神经学教授，同时担任大卫·A·库尔特老龄化与神经退行性疾病讲席教授，也是乔卡斯塔神经科学公司的联合创始人。随后，该技术被授权给总部位于某地的上市公司Unity Biotechnology, Inc.

San Francisco

旧金山

, in 2018. Unity developed Klotho protein for several years in multiple pre-clinical models before licensing the Klotho intellectual property and data package to Jocasta.

，于2018年。Unity在多个临床前模型中开发了Klotho蛋白多年，之后将Klotho的知识产权和数据包授权给了Jocasta。

'We were gratified by the exceptional investor interest during our raise and are delighted by the composition of the syndicate that includes both seasoned biotech investors as well as funds and individuals who believe our program has an opportunity to improve the lives of those who are stricken with cognitive decline — a testament to the potential of Klotho and the solid scientific foundation from Dr.

“我们在募资过程中得到了异常强烈的投资者兴趣，对此我们感到非常欣慰，并且很高兴看到这个财团的构成，其中包括经验丰富的生物技术投资者以及相信我们的项目有机会改善那些遭受认知能力下降的人们生活的基金和个人——这证明了Klotho的潜力以及来自博士的坚实科学基础。”

Dubal's work at the .

杜巴尔在工作。

University of California at San Francisco

加利福尼亚大学旧金山分校

,' said

，' 说

Albert Agro

阿尔伯特·阿格罗

, PhD, CEO of Jocasta.

，博士，乔卡斯塔首席执行官。

Co-founder

联合创始人

Michael Davidson

迈克尔·戴维森

has been integral to the company's mission by helping to articulate the potential of a - Klotho in promoting longevity. The team is comprised of leading experts in neuroscience and drug development, including Dr. Dubal, who will collaborate closely with management to advance the company's proprietary a - Klotho formulation through both preclinical and clinical development, with the goal of addressing cognitive decline linked to neurodegenerative diseases..

通过帮助阐明a-Klotho在促进长寿方面的潜力，已经成为公司使命的重要组成部分。该团队由神经科学和药物开发领域的领先专家组成，包括杜巴尔博士，他将与管理层密切合作，推动公司专有的a-Klotho配方在临床前和临床开发中的进展，目标是解决与神经退行性疾病相关的认知衰退问题。

a - Klotho's robust cognition enhancement has been demonstrated in multiple species, 11 cognitive tasks, and at five institutions. Jocasta is the leading company with an active program and exclusive IP with this novel therapeutic target. Clinical trials evaluating the effect of Jocasta's proprietary a - Klotho formulation are planned to begin in the next 18 months..

a-Klotho在多种物种、11项认知任务和五个机构中已显示出显著的认知增强效果。Jocasta是拥有此新型治疗靶点活跃项目和独家知识产权的领先公司。评估Jocasta专有a-Klotho配方效果的临床试验计划在未来18个月内开始。

'Having closely followed research in longevity for many years, we're thrilled to back this founding team as they tackle cognitive decline through a fundamentally different approach,' said

“在密切跟踪长寿研究多年后，我们很高兴能够支持这个创始团队，因为他们通过一种截然不同的方法来应对认知能力下降的问题，”

Kevin Rose

凯文·罗斯

, partner at True Ventures and media personality focused on the intersection of health and technology. 'Rather than treating symptoms, Jocasta is addressing the underlying biology with a -Klotho — a protein pathway that's shown remarkable potential but has been largely unexplored therapeutically. The team's deep expertise in both the science and clinical realities of aging gives them a unique advantage in translating this research into meaningful interventions for neurodegenerative disease.'.

True Ventures合伙人及媒体人，专注于健康与技术的交汇点。“Jocasta并非仅仅治疗症状，而是通过一种名为Klotho的蛋白质通路解决潜在的生物学问题，这一通路展现了显著的潜力，但在治疗方面却鲜有探索。该团队在衰老科学和临床现实方面的深厚专业知识，使他们拥有将这项研究转化为神经退行性疾病有效干预措施的独特优势。”

Media contact:

媒体联系人：

PR@jocastaneuro.com

About Jocasta Neuroscience

关于乔卡斯塔神经科学

Jocasta Neuroscience, Inc. is a pre-clinical stage biotech company focused on developing a proprietary formulation of a-Klotho protein (JN-0413) to manage cognitive decline associated with various forms of neurodegenerative-induced dementia. Jocasta's foundational data demonstrates the critical role of a-Klotho in health and disease.

乔卡斯塔神经科学公司（Jocasta Neuroscience, Inc.）是一家处于临床前阶段的生物技术公司，专注于开发一种专有的α-Klotho蛋白（JN-0413）配方，以应对由各种神经退行性疾病引发的痴呆所导致的认知衰退。乔卡斯塔的基础数据展示了α-Klotho在健康与疾病中的关键作用。

Results ranging from human genetics (effect of KL mutations in humans) to robust cognitive enhancement in healthy rats, rodent disease models and non-human primates strongly support the advancement of JN-0413 into clinical trials in patients with dementia and cognitive decline..

从人类遗传学（KL突变在人类中的影响）到健康大鼠、啮齿动物疾病模型和非人灵长类动物的强大认知增强结果，强烈支持将JN-0413推进到痴呆和认知衰退患者的临床试验中。

SOURCE Jocasta Neurosciences Inc.

来源：乔卡斯塔神经科学公司

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻吗

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers